Shalin Sanghvi, MD
Nephrology · Springfield, ORNPI 1366490914
Payments from drug & device makers
What this record shows
This record is dominated by other: $18,883 of the $19,644 with a category attached, or 96.1%. Angiodynamics, Inc. accounts for 96.1% of it on its own, with 11 other manufacturers making up the rest. Among nephrology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $503.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$19K
- Boston Scientific$249
- Medtronic$160
- Genentech USA, Inc.$93
- Otsuka America Pharmaceutical, Inc.$64
- Travere Therapeutics, Inc.$56
- plus $139 from 6 others
What the payments were for
- Food & beverage$7284%
- Education$320%
- Other$18,88396%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 3 | $18,883 |
| Boston Scientific | 16 | $249 |
| Medtronic | 1 | $160 |
| Genentech USA, Inc. | 2 | $93 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Travere Therapeutics, Inc. | 6 | $56 |
| Amgen | 2 | $35 |
| Bayer | 1 | $31 |
| Vifor Pharma, Inc. | 2 | $24 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,644 in reported general payments places this provider in the 95th percentile of 120 nephrology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 239 | $206,969 |
| FarxigaDapagliflozin Propanediol | 52 | $65,226 |
| LokelmaSodium Zirconium Cyclosilicate | 26 | $18,368 |
| Cinacalcet Hcl | 85 | $8,666 |
| Losartan Potassium | 263 | $3,312 |
| Torsemide | 153 | $3,207 |
| Eplerenone | 22 | $3,194 |
| Sevelamer Carbonate | 30 | $3,147 |
| Calcitriol | 140 | $2,723 |
| Amlodipine Besylate | 264 | $2,501 |
| Carvedilol | 165 | $1,752 |
| Olmesartan Medoxomil | 63 | $1,707 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,587 |
| Tamsulosin Hcl | 70 | $1,309 |
| Lisinopril | 145 | $1,301 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Springfield
- Ramesh MarahattaSpringfield$19K
- Anthony de MorySpringfield$743
- Michael MalleaSpringfield$614
- Mary LabibSpringfield$512
- Neil KumarRoseburg$532K
- Robert ProvenzanoPortland$45K
- Cyril KuriakoseTualatin$36K
- Nayan AroraPortland$23K
- Rupali AvasarePortland$16K
- David EllisonPortland$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.